02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Defactinib: Phase II suspended enrollment

Verastem stopped enrollment in the double-blind, international, pivotal Phase II COMMAND trial in patients with MPM after a pre-planned interim analysis showed that twice-daily 400 mg oral defactinib led to no difference in PFS, the...
00:52 , Sep 29, 2015 |  BC Extra  |  Clinical News

Verastem halts mesothelioma trial

Verastem Inc. (NASDAQ:VSTM) fell $3.82 (67%) to $1.85 on Monday after it halted enrollment of the Phase II COMMAND study of defactinib ( VS-6063 ) to treat mesothelioma due to futility. A DSMB found no...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Overcoming origins

The start of two large-scale trials enrolling patients whose tumors share a common molecular signature regardless of the tissue of origin reflects tremendous progress in both the understanding of cancer biology and the availability of...
07:00 , Sep 30, 2013 |  BioCentury  |  Strategy

FAKs of life

Verastem Inc. believes it is on track to reach the market in 2017 after starting a pivotal study of its lead FAK inhibitor to treat mesothelioma. If the plan succeeds, that will be three years...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

GSK2256098: Phase I data

An open-label, international Phase I trial in 29 patients with recurrent mesothelioma showed that twice-daily oral GSK2256098 produced 14 cases of stable disease. Median progression-free survival (PFS) was 17.7 weeks. In patients with neurofibromin 2...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Neurofibromin 2 (NF2; Merlin); angiomotin (AMOT) Cell culture and mouse studies suggest that inhibiting AMOT could help treat NF2-mutant cancers....